Evidence map›Paper›PMID 40508156›Full record

ArticleInternational journal of molecular sciences2025

Transforming Properties of E6/E7 Oncogenes from Beta-2 HPV80 in Primary Human Fibroblasts.

Francisco Israel Renteria-Flores, Andrea Molina-Pineda, Ruben Piña-Cruz, Sayma Vizcarra-Ramos, Alejandra Natali Vega-Magaña, Mariel García-Chagollán, María Teresa Magaña-Torres, Rodolfo Hernández-Gutiérrez, Adriana Aguilar-Lemarroy, Luis Felipe Jave-Suárez

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Francisco Israel Renteria-FloresPrograma de Doctorado en Ciencias en Biología Molecular y Medicina, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0002-3527-6889
Andrea Molina-PinedaUnidad de Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco A.C. (CIATEJ), Guadalajara 44270, Jalisco, Mexico.ORCID 0000-0002-8313-1932
Ruben Piña-CruzPrograma de Doctorado en Ciencias en Biología Molecular y Medicina, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0009-0009-8580-8714
Sayma Vizcarra-RamosDivisión de Inmunología, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0001-9967-8732
Alejandra Natali Vega-MagañaLaboratorio de Investigación en Cáncer e Infecciones, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0003-4749-2498
Mariel García-ChagollánInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
María Teresa Magaña-TorresDivisión de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico.
Rodolfo Hernández-GutiérrezUnidad de Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco A.C. (CIATEJ), Guadalajara 44270, Jalisco, Mexico.ORCID 0000-0001-7566-6825
Adriana Aguilar-LemarroyDivisión de Inmunología, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0001-9288-4824
Luis Felipe Jave-SuárezDivisión de Inmunología, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social (IMSS), Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0001-6209-5031

Funding

Fondo de Investigación en Salud (FIS) - Instituto Mexicano del Seguro Social (IMSS) FIS/IMSS/ PROT/EMER18/1844
6 · The paper itself

Abstract

Cervical cancer is the second leading cause of cancer-related death in Mexico, primarily due to persistent infection with high-risk Alpha-papillomavirus genotypes, such as HPV16 and 18. Next-generation sequencing (NGS) has revealed a high prevalence of Beta- and Gamma-HPVs, mainly Beta-2 types 38b, 80, 107, and 122, in cervical cancer samples from Mexico. Our group previously reported that HPVs 38b, 107, and 122 possess transforming properties in primary fibroblasts; however, the oncogenic potential of E6/E7-HPV80 has not yet been elucidated. For this purpose, primary human fibroblasts were transduced with E6/E7-HPV80 (FB-E6/E7-HPV80), and functional assays were conducted to evaluate changes in proliferation, metabolic activity, and cell migration. RNA-seq analysis identified differentially expressed genes (DEGs) and enriched pathways. Fibroblasts transduced with E6/E7-HPV16 (FB-E6/E7-HPV16) or empty vector (FB-pLVX) served as controls. FB-E6/E7-HPV80 extended their lifespan and exhibited increased proliferation, metabolic activity, and migration capacity. RNA-seq analysis identified 196 upregulated DEGs (such as

Indexed as

Cell Transformation, ViralFibroblastsOncogene Proteins, ViralPapillomavirus E7 ProteinsCell MovementCell ProliferationCells, CulturedFemaleHumansPapillomavirus InfectionsUterine Cervical NeoplasmsOncogene Proteins, ViralPapillomavirus E7 ProteinsBeta-2cervical cancerE6E7fibroblast modelHPVHPV80lentiviruspapillomavirus

Identifiers

PMID40508156
PMCPMC12154562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.